$15.21
0.26%
Nasdaq, Aug 29, 10:00 pm CET
ISIN
US4923271013
Symbol
KROS

Keros Therapeutics Inc Stock price

$15.21
+0.73 5.04% 1M
+4.13 37.27% 6M
-0.62 3.92% YTD
-30.10 66.43% 1Y
-21.44 58.50% 3Y
-38.33 71.59% 5Y
-4.87 24.25% 10Y
-4.87 24.25% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.04 0.26%
ISIN
US4923271013
Symbol
KROS
Industry

Key metrics

Basic
Market capitalization
$617.8m
Enterprise Value
$-72.5m
Net debt
positive
Cash
$690.2m
Shares outstanding
40.6m
Valuation (TTM | estimate)
P/E
33.1 | negative
P/S
2.7 | 3.1
EV/Sales
negative | negative
EV/FCF
negative
P/B
0.9
Financial Health
Equity Ratio
92.8%
Return on Equity
-32.8%
ROCE
0.0%
ROIC
0.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$232.8m | $201.6m
EBITDA
$1.7m | $-795.6k
EBIT
$312.0k | $-39.3m
Net Income
$18.8m | $-2.0m
Free Cash Flow
$53.1m
Growth (TTM | estimate)
Revenue
86,137.0% | 5,579.4%
EBITDA
100.9% | 99.6%
EBIT
100.2% | 81.4%
Net Income
111.2% | 99.0%
Free Cash Flow
136.3%
Margin (TTM | estimate)
Gross
-
EBITDA
0.7% | -0.4%
EBIT
0.1%
Net
8.1% | -1.0%
Free Cash Flow
22.8%
More
EPS
$0.5
FCF per Share
$1.3
Short interest
18.7%
Employees
169
Rev per Employee
$20.0k
Show more

Is Keros Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Keros Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Keros Therapeutics Inc forecast:

12x Buy
63%
7x Hold
37%

Analyst Opinions

19 Analysts have issued a Keros Therapeutics Inc forecast:

Buy
63%
Hold
37%

Financial data from Keros Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
233 233
86,137% 86,137%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 45 45
18% 18%
20%
- Research and Development Expense 187 187
24% 24%
80%
1.67 1.67
101% 101%
1%
- Depreciation and Amortization 1.36 1.36
31% 31%
1%
EBIT (Operating Income) EBIT 0.31 0.31
100% 100%
0%
Net Profit 19 19
111% 111%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Keros Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Keros Therapeutics Inc Stock News

Neutral
GlobeNewsWire
4 days ago
LEXINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announ...
Neutral
PRNewsWire
11 days ago
AUSTIN, Texas , Aug. 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "we"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released an open letter to Keros' Board of Directors (the "Board") expressing its disappointment with the Board's re...
Neutral
GlobeNewsWire
12 days ago
LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the U.S. Food...
More Keros Therapeutics Inc News

Company Profile

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Head office United States
CEO Jasbir Seehra
Employees 169
Founded 2015
Website www.kerostx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today